Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF.

Next Previous
Trial Profile

A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
  • Indications Laryngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Status changed from recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Primary endpoint has been met. (Specific survival) according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top